Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there. Did your doctor somehow miss the recovery protocol that Pedro Bach-y-Rita used to recover fully back in 1958 with only a partial brain?

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label triglyceride. Show all posts
Showing posts with label triglyceride. Show all posts

Monday, October 27, 2025

A comparative analysis of the cholesterol–high-density lipoprotein–glucose index and the triglyceride–glucose index in predicting in-hospital mortality in critically ill ischemic stroke patients

Survivors actually want you to do research that prevents this problem!  WITH NO LEADERSHIP IN STROKE NOTHNING EVER GETS DONE PROPERLY!

 A comparative analysis of the cholesterol–high-density lipoprotein–glucose index and the triglyceride–glucose index in predicting in-hospital mortality in critically ill ischemic stroke patients



Huang LuwenHuang LuwenLi LinlinLi LinlinYu Ming
&#x;Yu Ming*†Xu Lei
&#x;Xu Lei*†
  • Department of Neurology, Suining Central Hospital, Suining, Sichuan, China

Background: The Cholesterol, high-density lipoprotein, and glucose (CHG) index has emerged as a potential indicator of metabolic disturbance, but its prognostic value in patients with ischemic stroke (IS) remains unclear. This study aimed to assess whether the CHG index could predict 28-day in-hospital mortality in critically ill IS patients and to compare its performance with the established triglyceride–glucose (TyG) index.

Methods: We conducted a cohort analysis using data from the eICU database, involving 1,670 critically ill patients diagnosed with IS between 2014 and 2015. CHG and TyG indices were computed for each patient. Their associations with 28-day in-hospital mortality were examined using multivariable Cox regression. To further investigate the associations, restricted cubic spline (RCS) analysis was conducted. Kaplan–Meier curves were used to compare outcomes across different TyG and CHG groups. Predictive accuracy was compared using receiver operating characteristic (ROC) analysis. Subgroup analyses were performed to assess consistency across different clinical characteristics.

Results: Among the study population, 158 (9.46%) patients died within 28 days of hospitalization. The CHG index showed a greater association with mortality (HR 1.554; 95% CI 1.198–2.018; p < 0.001) compared to the TyG index (HR 1.436; 95% CI 1.175–1.755; p < 0.001) in unadjusted models, and both remained significant after adjustment. RCS analysis demonstrated a linear relationship between both indices and 28-day in-hospital mortality. ROC curves showed similar discriminatory ability for the CHG and TyG indices. No significant interactions were observed in subgroup analyses (p > 0.05; p for interaction >0.05).

Conclusions: Higher CHG index values are independently associated with increased 28-day mortality in critically ill IS patients, showing a linear relationship and predictive performance comparable to that of the TyG index.

Sunday, March 9, 2025

Association between blood triglycerides and stroke-associated pneumonia: a prospective cohort study

 Your competent? doctor has known of the pneumonia risk for years and a vaccine to possibly prevent that. But did your doctor DO ANYTHING?

The latest here:

Association between blood triglycerides and stroke-associated pneumonia: a prospective cohort study

Authors:
Xiujuan Yuan
Shicun Huang
Jianqiang Ni

Abstract and Figures

Background Cerebral infarction requires the reduction of blood lipids, but low triglycerides are associated with poor prognosis. stroke-associated pneumonia (SAP) can also lead to poor prognosis. Therefore, the purpose of this study is to investigate the correlation between triglycerides (TG) and SAP. Methods This prospective cohort study was conducted at the First Affiliated Hospital of Soochow University and enrolled consecutive patients with acute ischemic stroke admitted between March 2019 and March 2021. Univariate analysis, Multivariable logistic regression analysis, subgroup analysis, curve fitting, inflection point analysis, stratified and interaction analyses was performed to examine the relationship between blood TG and SAP. Results The study included 240 patients with acute ischemic stroke (92 females, mean age 68 years), of whom 94 developed SAP. Multivariate logistic regression analysis demonstrated that TG levels were independently associated with SAP. The fitting curve shows a linear relationship between TG level and SAP incidence, with a decrease in SAP incidence as TG increases. The inflection point value is TG = 2.6mmol/L. Conclusions The findings suggest that TG levels may be inversely associated with the risk of SAP in elderly patients with acute ischemic stroke.

Monday, December 11, 2023

New Study Finds That Cholesterol & Triglyceride Levels Might Help Predict Your Risk for Dementia—Here's What to Know

You'll have to ask your doctor how your levels compare to this. 

Your chances of getting dementia.

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018

New Study Finds That Cholesterol & Triglyceride Levels Might Help Predict Your Risk for Dementia—Here's What to Know

This study is another reminder that brain health and cardiovascular health are linked!

Getty Images
Getty Images© Provided by EatingWell
Reviewed by Dietitian Jessica Ball, M.S., RD

We know that yo-yo dieting and frequent blood sugar roller coasters do a number on our bodies. This week, we're learning more about the potential health harms related to fluctuations of another health factor: cholesterol.

According to a study published July 5, 2023 in the journal Neurology, individuals who have high variability in their total cholesterol and triglyceride levels—meaning large changes throughout the lifespan—appear to be at higher risk for developing dementia later in life compared to their more steady-cholesterol peers.


Wednesday, January 11, 2023

Dietary supplement can reverse the signs of heart disease in a subset of patients

WHOM do we contact to get this researched and tested in stroke patients?

Dietary supplement can reverse the signs of heart disease in a subset of patients

When we were little, our parents told us to take our vitamins so we could grow big and strong. Now, researchers from Japan find that one particular supplement may even fix a broken heart.

In a study that published recently in European Heart Journal, researchers from Osaka University have revealed that a dietary supplement can dramatically reverse the signs of heart disease in a subset of patients.

Coronary artery disease (CAD), which involves narrowing or even closing of the arteries of the heart and often leads to heart attack, is a major cause of death worldwide. Despite the existence of treatments such as cholesterol-lowering drugs and drug-eluting stents—a new stent technology for local drug delivery—death from this condition is still common, and some patients appear to be resistant to treatment.

Almost 15 years ago we identified a new type of CAD called triglyceride deposit cardiomyovasculopathy (TGCV), in which the coronary arteries are occluded by triglyceride deposits generated by defective intracellular breakdown of triglycerides in vascular smooth muscle cells. This mechanism makes TGCV distinct from classic cholesterol-induced atherosclerosis, and accounts for patients who are resistant to standard remedies for CAD."

Ken-ichi Hirano, lead author of the study

The researchers had developed diagnostic criteria for TGCV, and shown that this condition is especially prevalent in patients with diabetes mellitus and those who have undergone hemodialysis. Despite the ability to diagnose this condition, however, an effective treatment for these patients remained elusive.

"Now we report a remarkable regression of diffuse coronary atherosclerosis in two patients with TGCV," states Ken-ichi Hirano. "Both had suffered from refractory chest pain and diabetes until diagnosis with TGCV, and subsequent dietary intake of tricaprin led to symptom relief."

Tricaprin is a commercially available food supplement that promotes lipid breakdown by heart muscle cells. In addition to relieving these patients' troublesome and painful symptoms, tricaprin also resulted in remarkable regression of the triglyceride build-up in the blood vessels of the heart.

"While atherosclerosis regression following decreased serum lipid levels is well-described, this is the first report of regression due to increased triglyceride lipolysis within cells, and as such is a conceptually novel treatment for coronary atherosclerosis," says Ken-ichi Hirano.

Given that not all patients respond to current treatments for CAD, the findings from this study pave the way toward establishing a multi-faceted approach to CAD treatment. The dramatic results achieved by administering a readily available dietary supplement hold promise for patients who would otherwise continue to suffer the debilitating effects of this disease.

Source:
Journal reference:

Hirano, K., et al. (2023) Remarkable regression of diffuse coronary atherosclerosis in patients with triglyceride deposit cardiomyovasculopathy. European Heart Journal. doi.org/10.1093/eurheartj/ehac762.

Thursday, March 24, 2022

Blood Profile at Age 35 Linked to Subsequent Alzheimer's Dementia

 I have zero clue what my readings were 30 years ago. It makes zero difference, your doctor is responsible to have EXACT Alzheimer's prevention protocols right now at your current age.

Blood Profile at Age 35 Linked to Subsequent Alzheimer's Dementia

Associations extend much earlier in life than previously thought

A photo of a vial of blood and a butterfly catheter laying on lipid panel results.

High-density lipoprotein (HDL) cholesterol and triglyceride levels in people as young as age 35 were linked with Alzheimer's dementia decades later in life, longitudinal data from the Framingham Heart Study showed.

Risk of Alzheimer's dementia fell by 15.4% during early adulthood (ages 35 to 50) and by 17.8% during middle adulthood (ages 51 to 60) for every 15 mg/dL increase in HDL cholesterol, reported Xiaoling Zhang, MD, PhD, of Boston University School of Medicine, and co-authors in Alzheimer's & Dementia.

A 15 mg/dL increase in blood glucose measured during middle adulthood was associated with a 14.5% increased Alzheimer's risk, they added. Triglyceride levels were associated with Alzheimer's only in the early adulthood group. Findings remained significant after adjusting for treatment.

"These findings show for the first time that cardiovascular risk factors, including HDL, which has not been consistently reported as a strong risk factor for Alzheimer's disease, contribute to future risk of Alzheimer's disease starting as early as age 35," Zhang said in a statement.

"While our findings confirm other studies that linked cholesterol and glucose levels measured in blood with future risk of Alzheimer's disease, we have shown for the first time that these associations extend much earlier in life than previously thought," added co-author Lindsay Farrer, PhD, also of Boston University.

The researchers looked at the influence of vascular risk factors on incident Alzheimer's dementia over time among Framingham Heart Study Offspring participants, a group that's been evaluated since 1971. Data on lipid fractions, glucose, blood pressure, BMI, and smoking were obtained prospectively from participants across nine quadrennial examinations.

Age-, sex-, and education-adjusted models were tested for each risk factor measured at each exam and within three adult age groups: early adults (ages 35 to 50, median 41), middle adults (ages 51 to 60, median 54), and late adults (ages 61 to 70, median 63.5).

A total of 271 participants (167 women, 104 men) diagnosed with Alzheimer's dementia were included in the analysis as cases. Of these, 225 people were without stroke, 24 people had Alzheimer's and stroke, and 24 people had mixed Alzheimer's and vascular dementia. People with a diagnosis of non-Alzheimer's dementia were excluded. Controls included 4,867 cognitively normal participants.

Mean follow-up periods for people in the early, middle, and late age groups were 35.2 years, 25.8 years, and 18.5 years, respectively. As participants grew older, they tended to have higher triglyceride and glucose levels, higher systolic and diastolic blood pressure, and lower HDL cholesterol levels. They also were more likely to be treated for diabetes, hypertension, and dyslipidemia.

Incident Alzheimer's dementia was negatively associated with HDL cholesterol for every 15 mg/dL increase in early adulthood (HR 0.85, 95% CI 0.72-0.99, P=0.041) and in middle adulthood (HR 0.82, 95% CI 0.70-0.96, P=0.014). This association remained significant with a similar effect size in the middle adulthood group when adjusted for dyslipidemia treatment (P=0.022).

Analyses also showed:

  • Triglyceride levels were associated with Alzheimer's dementia only in the early adulthood group, before (HR 1.33, 95% CI 1.02-1.57, P=0.0013) and after (HR 1.30, 95% CI 1.10-1.54, P=0.0018) adjusting for dyslipidemia treatment
  • Blood glucose in middle adulthood was associated with Alzheimer's dementia per 15 mg/dL increase, before (HR 1.15, 95% CI 1.06-1.23, P=0.00029) and after (HR 1.18, 95% CI 1.08-1.29, P=0.00036) adjusting for diabetes treatment
  • Diastolic blood pressure in late adulthood was associated with Alzheimer's dementia per 10 mm increase, before (HR 1.14, 95% CI 1.01-1.29, P=0.041) and after (HR 1.14, 95% CI 1.00-1.29, P=0.044) adjusting for treatment
  • Other vascular risk factors, including low-density lipoprotein (LDL) cholesterol, total cholesterol, BMI, smoking, and systolic blood pressure, were not associated with Alzheimer's dementia in any stage of adulthood (P>0.05)

Future development of Alzheimer's dementia was progressively higher and likely to occur earlier among people who had blood glucose in pre-diabetic (100 to 126 mg/dL) and diabetic (>126 mg/dL) ranges in early adulthood and middle adulthood.

"Intervention targeting cholesterol and glucose management starting in early adulthood can help maximize cognitive health in later life," Farrer suggested.

That idea is supported by previous studies of Framingham Offspring participants showing that elevated coronary heart disease risk and metabolic syndrome were associated with lower cognitive performance at age 55, Zhang and co-authors noted.

"However, our results do not distinguish whether the influences of these risk factors on the development of Alzheimer's disease may be particularly damaging during early adulthood and midlife or reflect longer accumulated risk exposure," they wrote.

The study had several limitations, the researchers acknowledged. All participants were white, and some early measurements of lipids and glucose were not under fasting conditions. In addition, the findings were based on analyses of one-time measurements.

  • Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more. Follow

Disclosures

This work was supported by the Framingham Heart Study's National Heart, Lung, and Blood Institute contract, Boston University School of Medicine, the NIH, and the Alzheimer's Association.

Zhang had no disclosures.

Co-authors reported relationships with the Alzheimer's Drug Discovery Foundation, American Heart Association, Gates Ventures, Mass Mutual Insurance, Signant Health, Biogen, GlaxoSmithKline, Novo Nordisk, High Lantern, and the NIH.

 
 

Monday, June 29, 2020

A ‘Cure for Heart Disease’? A Single Shot Succeeds in Monkeys

A novel gene-editing experiment seems to have permanently reduced LDL and triglyceride levels in monkeys.





Credit...CMEABG-UCBL-Chapon/Science Source
What if a single injection could lower blood levels of cholesterol and triglycerides — for a lifetime?
In the first gene-editing experiment of its kind, scientists have disabled two genes in monkeys that raise the risk for heart disease. Humans carry the genes as well, and the experiment has raised hopes that a leading killer may one day be tamed.
“This could be the cure for heart disease,” said Dr. Michael Davidson, director of the Lipid Clinic at the University of Chicago Pritzker School of Medicine, who was not involved in the research.
But it will be years before human trials can begin, and gene-editing technology so far has a mixed tracked record. It is much too early to know whether the strategy will be safe and effective in humans; even the monkeys must be monitored for side effects or other treatment failures for some time to come.

Continue reading the main story
The results were presented on Saturday at the annual meeting of the International Society for Stem Cell Research, this year held virtually with about 3,700 attendees around the world. The scientists are writing up their findings, which have not yet been peer-reviewed or published.
The researchers set out to block two genes: PCSK9, which helps regulate levels of LDL cholesterol; and ANGPTL3, part of the system regulating triglyceride, a type of blood fat. Both genes are active in the liver, which is where cholesterol and triglycerides are produced. People who inherit mutations that destroyed the genes’ function do not get heart disease.
People with increased blood levels of triglycerides and LDL cholesterol have dramatically greater risks of heart disease, heart attacks and strokes, the leading causes of death in most of the developed world. Drug companies already have developed and are marketing two so-called PCSK9 inhibitors that markedly lower LDL cholesterol, but they are expensive and must be injected every few weeks.
Researchers at Verve Therapeutics, led by Dr. Sekar Kathiresan, the chief executive, decided to edit the genes instead. The medicine they developed consists of two pieces of RNA — a gene editor and a tiny guide that directs the editor to a single sequence of 23 letters of human DNA among the genome’s 3.25 billion so-called base pairs.
The RNA is shrouded in tiny lipid spheres to protect the medicine from being instantly degraded in the blood. The lipid spheres travel directly to the liver where they are ingested by liver cells. The contents of the spheres are released, and once the editor lands on its target, it changes a single letter of the sequence to another — like a pencil erasing one letter and writing in another.
Advertisement
Continue reading the main story
Not only did the system work in 13 monkeys, the researchers reported, but it appeared that every liver cell was edited. After gene editing, the monkeys’ LDL levels dropped by 59 percent within two weeks. The ANGPTL3 gene editing led to a 64 percent decline in triglyceride levels.
One danger of gene editing is the process may result in modification of DNA that scientists are not expecting. “You will never be able to have no off-target effects,” warned Dr. Deepak Srivastava, president of the Gladstone Institutes in San Francisco.
In treating a condition as common as heart disease, he added, even an uncommon side effect can mean many patients are affected. So far, however, the researchers say that they have not seen any inadvertent editing of other genes.
Another question is how long the effect on cholesterol and triglyceride levels will last, Dr. Davidson said. “We hope it will be one-and-done, but we have to validate that with clinical trials,” he said.
Jennifer Doudna, a biochemist of the University of California, Berkeley, and a discoverer of Crispr, the revolutionary gene editing system, said: “In principle, Verve’s approach could be better because it’s a one-time treatment.”
But it is much too soon to say if it will be safe and long-lasting, she added.
If the strategy does work in humans, its greatest impact may be in poorer countries that cannot afford expensive injections for people at high risk of heart disease, said Dr. Daniel Rader, chairman of the department of genetics at the University of Pennsylvania and a member of Verve’s scientific advisory board.
Dr. Kathiresan, of Verve, noted that half of all first heart attacks end in sudden death, making it imperative to protect those at high risk.
Advertisement
Continue reading the main story
Dr. Kathiresan began the research at the Massachusetts General Hospital and the Broad Institute, where he and his colleagues found a collection of genes that increase risk of heart attack at a relatively young age, as well as eight genes that, when mutated, decrease risk.
Those protective genes, he reasoned, could be targets for gene editing if there were a way to alter them in people. Gene editing is only now succeeding, and so far its successes have been in rare diseases.
Other investigators and companies have tried editing genes in mice to prevent heart disease, with some success, but primates are a much more difficult challenge.
Dr. Kathiresan said that to his knowledge, his study is the first to use the pencil-and-eraser type gene editing in primates for a very common disease. Verve licensed the technology, called base editing, from Beam Therapeutics.
If all goes well, Dr. Kathiresan hopes in a few years to begin treating people who have had heart attacks and still have perilously high cholesterol. For them, the risk of another heart attack is so high that the possible benefit may far outweigh the risks of the treatment.
Heart disease generally occurs only after decades of high cholesterol levels, Dr. Davidson noted. By age 50, people most likely to have a heart attack already have a significant accumulation of plaque in their arteries.
But if the PCSK9 gene could be knocked out in 20-year-olds, he said, “there would be no heart disease in their future.”

Thursday, January 16, 2020

FDA approves CV event risk reduction indication for icosapent ethyl

You will have to ask your doctor if CVD used in this context means strokes also. Or are they so fucking out-of-date that they missed the WHO reclassified stroke in 2006, now a neurological disease not cardiovascular disease?

FDA approves CV event risk reduction indication for icosapent ethyl


Deepak L. Bhatt
The FDA on Friday approved the use of icosapent ethyl as an adjunctive therapy to reduce the risk for CV events among adults with elevated triglyceride levels, according to an agency press release.
Patients must also have either established CVD or diabetes and two or more additional risk factors for CVD.
Icosapent ethyl (Vascepa, Amarin) is the first FDA-approved drug to reduce CV risk among adults with elevated triglycerides as an add-on to maximally tolerated statin therapy.
The drug first netted approval in July 2012 for the reduction of triglycerides in adults with severe hypertriglyceridemia.
In November, the expanded indication to reduce risk for CV events was discussed during an Endocrinologic and Metabolic Diseases Advisory Committee of the FDA meeting. As Healio previously reported, the committee voted 16-0 in favor of the safety and efficacy of icosapent ethyl, based on available data, to support this indication.
“First, the unanimous 16-0 vote by the independent FDA advisory committee and now this formal FDA label expansion for CV risk reduction really endorse the strength of our findings from REDUCE-IT regarding

after the WHO reclassified stroke in 2006, now a neurological disease not cardiovascular disease.

,” Cardiology Today Editorial Board Member Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, told Healio.
The FDA evaluated data from REDUCE-IT, which included 8,179 adults aged 45 years and older with a history of CAD, cerebrovascular disease, carotid artery disease and/or peripheral artery disease, or adults aged 50 years and older with diabetes and additional risk factors for CVD. REDUCE-IT demonstrated that icosapent ethyl was superior to placebo for reducing risk for ischemic events in patients with elevated triglycerides at high CV risk despite statin therapy. In March, new data from the REDUCE-IT trial demonstrated a 30% reduction in total ischemic events, including first and subsequent events, in high-risk patients with elevated triglycerides.
“The independent Institute for Clinical and Economic Review group found icosapent ethyl to be highly cost-effective, and William Weintraub, MD, just presented our REDUCE-IT patient-level cost-effectiveness data at the American Heart Association Scientific Sessions, finding icosapent ethyl to be ‘dominant,’ or cost-saving, in the majority of cases. That is something that is quite rare in cost-effectiveness research,” Bhatt said in an interview. “Multiple professional society guidelines such as the American Diabetes Association, European Society of Cardiology/European Atherosclerosis Society and National Lipid Association, have already incorporated the REDUCE-IT findings for secondary prevention and diabetic primary prevention, and now there is an FDA label that also backs that approach. So, at this time, the key challenge is to now identify and treat appropriate patients — a large population that stands to benefit substantially from this novel therapeutic approach.”
In a statement released Friday, John F. Thero, president and CEO of Amarin, said the expanded indication for icosapent ethyl offers a new option for people with persistent CV risk despite the use of statins with other contemporary standard-of-care therapies.
“We aim to help millions of high-risk patients, including statin-treated patients and statin-intolerant patients,” Thero said in the release. “For the first time, physicians, patients and payers have an FDA-approved treatment option beyond cholesterol lowering that has been demonstrated to significantly reduce major adverse cardiovascular events when used on top of a statin. We look forward to helping educate physicians and patients on the value of Vascepa. The expanded indication and related clinical study labeling is broadly worded, informative on the many effects of Vascepa and will empower physicians with critical information to help them apply their clinical judgment in addressing cardiovascular disease risk for patients in need.”

Michael Miller
Healio also spoke with Michael Miller, MD, professor of cardiovascular medicine, epidemiology and public health and director of the Center for Preventive Cardiology at University of Maryland School of Medicine in Baltimore, about this FDA approval. He said, “This is a huge victory for so many of our patients because nearly one out of every three men and women in the U.S. has a triglyceride of at least 150 mg/dL, and millions of these patients have CVD or have diabetes plus multiple CV risk factors.”

Icosapent ethyl’s active ingredient is the omega-3 fatty acid, eicosapentaenoic acid, derived from fish oil.
In clinical trials, icosapent ethyl was associated with an increased risk for atrial fibrillation requiring hospitalization. The incidence of AF was greater among patients with a history of AF or atrial flutter. Icosapent ethyl was also associated with an increased risk for bleeding events. The incidence of bleeding was higher among individuals taking other medications that increase the risk for bleeding, such as aspirin, clopidogrel or warfarin.
The FDA noted that people with allergies to fish or shellfish should be advised about the potential for allergic reactions. The most common adverse effects reported in the clinical trials for icosapent ethyl were musculoskeletal pain, peripheral edema, AF and arthralgia. – by Regina Schaffer, with additional reporting from Darlene Dobkowski
For more information:
Deepak L. Bhatt, MD, MPH, can be reached at dbhatt@bwh.harvard.edu; Twitter: @dlbhattmd.
Michael Miller, MD, can be reached at Cardiovascular Medicine, 110 South Paca St., Suite 7N-124, Baltimore, MD 21201; email: mmiller@som.umaryland.edu; Twitter: @mmillermd1.
Disclosures: Bhatt reports he received research funding from Amarin to Brigham and Women’s Hospital for his role as a study chair and is principal investigator of the REDUCE-IT trial. Miller reports he is a steering committee member for the REDUCE-IT trial and a scientific advisor for Amarin. Thero is president and CEO of Amarin.

Tuesday, December 11, 2018

REDUCE-IT: Icosapent ethyl reduces ischemic events in high-risk patients

Maybe in a couple of decades our researchers will finally have stroke put into the neurological disease category instead of the cardiovascular category.  Until then you will need to monitor CVD research. The WHO reclassified stroke in 2006, now a neurological disease not cardiovascular disease. So only 12 years of incompetency. 

REDUCE-IT: Icosapent ethyl reduces ischemic events in high-risk patients


Deepak L. Bhatt
Deepak L. Bhatt
CHICAGO — In patients with elevated triglycerides at high CV risk despite statin therapy, icosapent ethyl was superior to placebo for reducing risk for ischemic events, according to results of the anticipated REDUCE-IT trial.
The trial of icosapent ethyl (Vascepa, Amarin Pharmaceuticals), a pharmaceutical-grade omega-3 fatty acid, enrolled 8,179 patients (median age, 64 years; 71% men) who had fasting triglycerides 135 mg/dL to 499 mg/dL despite taking statins and who had established CVD (70.7%) or diabetes plus other risk factors (29.3%). Patients were assigned icosapent ethyl 2 g twice daily or placebo and followed for a median of 4.9 years. All had LDL levels ranging from 41 mg/dL to 100 mg/dL.

Reduction in CV events
The primary endpoint of CV death, nonfatal MI, nonfatal stroke, coronary revascularization or unstable angina occurred less often in the icosapent ethyl group compared with the placebo group (17.2% vs. 22%; HR = 0.75; 95% CI, 0.68-0.83; P = .00000001; absolute difference, 4.8%; 95% CI, 3.1-6.5; number needed to treat to prevent one primary endpoint event = 21; 95% CI, 15-33), Cardiology Today’s Intervention Chief Medical Editor Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, reported at the American Heart Association Scientific Sessions.
“Treatment with icosapent ethyl significantly reduced cardiovascular events, including a 20% reduction in cardiovascular death, a 31% reduction in heart attack, a 28% reduction in stroke and a low rate of adverse events,” Bhatt said during a presentation. “There was a consistent benefit across all subgroups, including in the primary and secondary prevention cohorts.”
The key secondary endpoint, defined as CV death, nonfatal MI or nonfatal stroke, was also lower in the icosapent ethyl group (11.2% vs. 14.8%; HR = 0.74; 95% CI, 0.65-0.83; P = .0000006; absolute difference, 3.6%; 95% CI, 2.1-5; number needed to treat to prevent one key secondary endpoint event = 28; 95% CI, 20-47).
The researchers also performed hierarchical testing of additional ischemic endpoints. In this analysis, the rates of the additional ischemic endpoints, including death from CV causes, were also lower in the icosapent ethyl group (4.3% vs. 5.2%; HR = 0.8; 95% CI, 0.66-0.98).
Carl E. Orringer
Carl E. Orringer
“The highly significant reductions in the primary and secondary cardiovascular endpoints in the presence of relatively modest effects of blood lipids and lipoproteins suggest the possibility that other properties of this drug such as the antithrombotic or anti-inflammatory effects” could have prompted the results, Carl E. Orringer, MD, FACC, FNLA, associate professor of medicine at University of Miami Miller School of Medicine, said during a discussant presentation at the press conference.

Tuesday, July 11, 2017

Rethinking good cholesterol A high HDL cholesterol level may not be as beneficial as once believed.

What does your doctor think?
http://www.health.harvard.edu/heart-health/rethinking-good-cholesterol?utm_source=delivra&utm_medium=email&utm_campaign=WR20170707-Cholesterol&utm_id=557639&dlv-ga-memberid=10994398&mid=10994398&ml=557639
If you're hoping to avoid heart disease, you probably keep tabs on your blood cholesterol values — especially your low-density lipoprotein (LDL), or "bad" cholesterol. Too much LDL in the bloodstream helps to create the plaque that accumulates inside arteries, raising the risk of a heart attack. The lower your LDL, the lower your risk of having a heart attack.
In contrast, high-density lipoprotein (HDL) has long been known as the "good" cholesterol. These particles are known to patrol blood vessels, grabbing cholesterol from both the bloodstream and artery walls and ferrying it to the liver for recycling and disposal. In population-based studies, people with high HDL levels tend to have fewer heart attacks, while those with lower HDL values have more.

HDL: Just a bystander?

But the HDL story is more complex than doctors initially thought. It turns out that not all HDL is created equal (see "The many faces of HDL"). Instead of acting as the good guy that helps lower heart disease risk, HDL may be more of a bystander.
"We're now realizing that HDL appears to be a marker for other factors that raise or lower the risk of a heart attack," says Dr. Christopher Cannon, professor of medicine at Harvard Medical School and a cardiologist at Brigham and Women's Hospital.
People with low HDL levels (see "Lipid lowdown: The numbers to know") tend to have other problems closely linked to higher cardiovascular risk, such as being overweight and having diabetes. "When you see a low HDL value, it's often a middle-aged man with a big belly who has high blood sugar and high blood pressure," says Dr. Cannon. It may be that those factors, rather than the low HDL, are behind the higher risk, he explains.

The many faces of HDL

Cholesterol, a waxy, pale yellow lipid, travels through the bloodstream in tiny, protein-covered particles called lipoproteins that mix easily with blood. While low-density lipoproteins (LDL) are rich in cholesterol, high-density lipoproteins (HDL) contain more protein. But that's just the beginning: there are also very-low-density and intermediate-density particles, as well as subcategories within these different lipoprotein classes.
HDL, for example, comes in different shapes and sizes. Some types are spherical, while others are doughnut-shaped. Some types of HDL are great at plucking cholesterol from LDL and artery walls, while other types are indifferent to cholesterol, and some even transfer cholesterol the wrong way — into LDL and cells.
Researchers are investigating this phenomenon using a test known as cholesterol efflux capacity testing. Currently available only in research settings, the test reveals how effective HDL particles are at moving cholesterol out of plaques and back to the liver. Preliminary findings suggest that high scores are linked to a lower heart disease risk, meaning the test might one day prove useful for predicting heart attack risk.

Genetic research and drug trials

But two major lines of evidence have also put HDL in a less-than-positive light. The first comes from studies of people with genetic mutations that cause high HDL. If high HDL truly protects against heart disease, those people should have fewer heart attacks. But they don't — they're just as likely to have heart disease as people without HDL-raising mutations. The second body of evidence is perhaps even more incriminating: To date, five major clinical trials that sought to raise HDL levels with drugs have failed to lower heart disease risk. These trials included several investigational new drugs as well as an old standby, niacin. Many people continue to take niacin, despite the fact that last year, the FDA withdrew its approval for using niacin-containing drugs as add-on drugs for treating cholesterol problems, Dr. Cannon notes.
What does all this mean for people with low HDL? Think of it as a warning to pay attention to your other numbers, especially your LDL, which should still be your primary focus. Aim for an LDL of 100 or lower, ideally through lifestyle changes such as weight loss, a healthy diet, and exercise, plus cholesterol-lowering statins, if indicated. These measures — especially exercise — may also nudge up your HDL. Vigorous workouts that make you sweat seem to be the most effective.
On the flip side, people with high HDL shouldn't assume that it cancels out a high LDL, as some physicians still believe. Again, your main goal should be to keep your LDL in a healthy range, Dr. Cannon says.
Lipid lowdown: The numbers to know
Test General desirable level
Total cholesterol Under 200mg/dL
LDL cholesterol Under 100 mg/dL
HDL cholesterol Over 40 mg/dL for a man, over 50 mg/dL for a woman
Tryglycerides Under 150 mg/dL